We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Global Point-of-Care Coagulation Testing Market to Be Driven by Growing Geriatric Population

By LabMedica International staff writers
Posted on 08 Dec 2021
Print article
Illustration
Illustration

The global point-of-care (POC) coagulation testing market is set to achieve significant growth on the back of the growing geriatric population and increasing technological innovations in POC testing, although the lack of trained professionals will hamper market growth.

These are the latest findings of Technavio (New York, NY, USA), a global technology research and advisory company.

The growing geriatric population is expected to fuel the growth of the POC coagulation testing market. Aging increases the susceptibility to infections as the immune system deteriorates with age. Older adults require diagnostic testing on a regular basis due to their low immunity and slow metabolism. These factors have increased the demand for POC blood coagulation analyzers as coagulation measurements can assist in diagnosing diseases. Physicians use the results of these blood tests to choose the most suitable line of treatment. Hence, an increasing older adult population indicates a growing demand for POC coagulation testing, thus contributing to the market growth.

However, the inability to hire trained professionals will limit the use of POC coagulation analyzers, which could hinder market growth. There is a shortage of these specialists in diagnostic centers and hospitals globally. Generally, most rural hospitals face issues such as the lack of patient volume required to justify having specialists. Most times, appointing in-house specialists is cost-prohibitive, especially for small medical facilities. Therefore, end-users such as hospitals and diagnostic centers will need to invest significantly in providing training to their employees for laboratory testing and maintaining POC coagulation analyzers.

The hospitals and clinics segment hold the largest share of the global POC coagulation testing market and will be the key driver of the market growth, owing to the significant use of POC coagulation testing analyzers during perioperative procedures for the timely determination of coagulopathies (bleeding disorders) and hemostatic functions in patients. This helps in preventing unanticipated bleeding and perioperative mortality. Hospitals and clinics use globally accepted POC coagulation testing procedures such as aPTT and INR, which significantly reduce the turnaround time and allow medical practitioners to make fast decisions during critical situations.

Geographically, a majority of the growth of the global POC coagulation testing market will originate from North America due to an increase in laboratory automation, a shift toward rapid diagnostic tests, and increased number of Food & Drug Administration (FDA) approvals for new diagnostic procedures such as liquid biopsy and microbial tests. The US is a key market for POC coagulation testing in North America. However, the North American market for POC coagulation testing is expected to grow at a slower pace than the market in Asia and Europe.

Related Links:
Technavio 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
Pipet Controller
Stripettor Pro

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.